Jolanta Weglowska

Week Patients | Phase 3 Studies | Brodalumab Placebo | Plaque Psoriasis | Safety Ixekizumab

Prominent publications by Jolanta Weglowska

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

[ PUBLICATION ]

KOL Index score: 20967

BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.

METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were ...

Also Ranks for: Brodalumab Patients | placebo week | phase 3 studies | ustekinumab psoriasis | monoclonal antibodies

Jolanta Weglowska: Influence Statistics

Sample of concepts for which Jolanta Weglowska is among the top experts in the world.
Concept	World rank
Type to filter list:
comparing brodalumab	#43
ixekizumab maintenance	#44
amagine2 amagine3	#45
received ixekizumab	#47
receive brodalumab	#51
amagine3	#53
210 brodalumab	#61
brodalumab ustekinumab	#62
amagine2	#62
moderatetosevere psoriasis brodalumab	#64
higher brodalumab	#64
receiving brodalumab	#66
placebo brodalumab	#69
monoclonal humanized candidiasis	#70
brodalumab week	#74
210 140	#75
brodalumab placebo	#89

Key People For Week Patients

Top KOLs in the world

Paul Emery

rheumatoid arthritis ankylosing spondylitis radiographic progression

Josef Sebastian Smolen

rheumatoid arthritis systemic lupus erythematosus radiographic progression

Désirée M F M van der Heijde

rheumatoid arthritis ankylosing spondylitis radiographic progression

Maxime R DOUGADOS

rheumatoid arthritis ankylosing spondylitis desir cohort

Arthur F Kavanaugh

psoriatic arthritis celgene corporation week patients

Philip J Mease

psoriatic arthritis eli lilly novartis pfizer

Select a search phrase week patients , week patients uc , week patients qol , week patients life , week patients age

Jolanta Weglowska:Expert Impact

Concepts for whichJolanta Weglowskahas direct influence:Week patients, Brodalumab patients, Patients brodalumab, Phase 3 studies, Placebo week, Brodalumab placebo, Plaque psoriasis, Placebo brodalumab.

Jolanta Weglowska:KOL impact

Concepts related to the work of other authors for whichfor which Jolanta Weglowska has influence:Plaque psoriasis, Psoriatic arthritis, Monoclonal antibodies, Brodalumab patients, Th17 cells, Biologic agents, Atopic dermatitis.

Tools

Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile https://www.keyopinionleaders.com/Week-Patients/Jolanta-Weglowska-For-The-IxoraPeds-Investigators--Niepu-d32c7387d011daf3b777d3ab41930056-zb.html

for the IXORA-PEDS Investigators | Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław (J.W.), and Lubelskie Centrum Diagnostyczne, Świdnik (T.B.) — both in Poland